Applying Population Dynamics Modeling to Patients With Lymph Node Positive Prostate Cancer

Journal of Urology

Volumn 178, Issue 5, 2007, Pages 1952-1956

  Johnstone, Peter A S ^a   Riffenburgh, Robert H ^c   Rossi, Peter J ^a   Assikis, Vasily ^b   Master, Viraj A ^a   Jani, Ashesh B ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Peachtree Hematology Oncology Consultants   (United States)

^c NAVAL MEDICAL CENTER SAN DIEGO   (United States)

Author keywords

lymph nodes; mortality; prostate; prostatic neoplasms; SEER program

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE COURSE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; POPULATION DYNAMICS; PRIORITY JOURNAL; PROSTATE CANCER;

FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MODELS, STATISTICAL; POPULATION DYNAMICS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SEER PROGRAM; SURVIVAL RATE; TIME FACTORS; UNITED STATES;

EID: 35148842827     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.07.017     Document Type: Article

References (17)

1. Riffenburgh R.H. A new method for estimating parameters for the Gompertz growth curve. J Conseil Int Explor Mer 25 (1960) 285
2. Brody S. Bioenergetics and Growth (1945), Reinhold, New York
3. Weymouth F.W., and McMillin H.C. Relative growth and mortality of the Pacific razor clam (Siliqua patula Dixon) and their bearing on commercial fishery. Bull U S Fish Comm 46 (1930) 543
4. Riffenburgh R.H., and Johnstone P.A.S. Survival patterns of cancer patients. Cancer 91 (2001) 2469
5. Johnstone P.A.S., Norton M.S., and Riffenburgh R.H. Survival of patients with untreated breast cancer. J Surg Oncol 73 (2000) 273
6. Adriano E, Harrison T, Riffenburgh RH and Johnstone PAS: Survival of patients with untreated cervical cancer. Presented at meeting of American Radium Society, Napa Valley, California, April 26-29, 2001.
7. Gompertz B. On the nature of the function expressive of the law of human mortality, and on a new mode of determining the value of live contingencies. Phil Trans 115 (1825) 513
8. American Joint Committee on Cancer. Manual for Staging of Cancer. 5th ed. (1997), JB Lippincott, Philadelphia
9. Messing E.M., Manola J., Sarosdy M., Wilding G., Crawford E.D., and Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341 (1999) 1781
10. Bolla M., van Poppel H., Collette L., van Cangh P., Vekemans K., Da Pozzo L., et al., European Organization for Research and Treatment of Cancer. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366 (2005) 572
11. Thompson Jr. I.M., Tangen C.M., Paradelo J., Lucia M.S., Miller G., Troyer D., et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296 (2006) 2329
12. Wiegel T., Bottke D., Willich N., Piechota H.J., Souchon R., Stoeckle C., et al. Phase III results of adjuvant radiotherapy (RT) versus "wait and see" (WS) in patients with pT3 prostate cancer following radical prostatectomy (RP) (ARO 96-02/AUO AP 09/95). Proc Am Soc Clin Oncol 23 (2005) 381s abstract 4513
13. Johnstone P.A., Assikis V., Goodman M., Ward K.C., Riffenburgh R.H., and Master V. Lack of survival benefit of post-operative radiation therapy in prostate cancer patients with positive lymph nodes. Prostate Cancer Prostatic Dis 10 (2007) 185
14. Lawton C.A., Winter K., Grignon D., Pilepich M.V., and Radiation Therapy Oncology Group 85-31. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial. J Clin Oncol 23 (2005) 800
15. Roach III M., DeSilvio M., Lawton C., Uhl V., Machtay M., Seider M.J., et al., Radiation Therapy Oncology Group 9413. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21 (2003) 1904
16. Bader P., Burkhard F.C., Markwalder R., and Studer U.E. Is a limited lymph node dissection an adequate staging procedure for prostate cancer. J Urol 168 (2002) 514
17. Bader P., Burkhard F.C., Markwalder R., and Studer U.E. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure. J Urol 169 (2003) 849